Regeneron, Ultragenyx Ink International Deal on Cholesterol Drug Evkeeza

By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. on Friday said they signed an international licensing agreement for Regeneron's cholesterol drug Evkeeza.

Under the agreement, Ultragenyx, a Novato, Calif., biopharmaceutical company, will develop, commercialize and distribute Evkeeza in countries outside the U.S., including in the European Economic Area, where Evkeeza was approved in June 2021.

Regeneron will receive a $30 million upfront payment and is eligible to receive up to $63 million in potential regulatory and sales milestones, the companies said.

Tarrytown, N.Y., biotechnology company Regeneron discovered Evkeeza and launched the drug in the U.S. last February for patients with homozygous familial hypercholesterolemia, an ultra-rare inherited form of high cholesterol. Regeneron said it will continue to solely sell Evkeeza in the U.S.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

01-07-22 0734ET